CN105828821B - 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 - Google Patents

具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 Download PDF

Info

Publication number
CN105828821B
CN105828821B CN201480069586.5A CN201480069586A CN105828821B CN 105828821 B CN105828821 B CN 105828821B CN 201480069586 A CN201480069586 A CN 201480069586A CN 105828821 B CN105828821 B CN 105828821B
Authority
CN
China
Prior art keywords
vortioxetine
nalmefene
active
treatment
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480069586.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105828821A (zh
Inventor
C·S·莫里洛
G·N·斯梅金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105828821(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN105828821A publication Critical patent/CN105828821A/zh
Application granted granted Critical
Publication of CN105828821B publication Critical patent/CN105828821B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480069586.5A 2013-12-20 2014-12-18 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 Active CN105828821B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (2)

Publication Number Publication Date
CN105828821A CN105828821A (zh) 2016-08-03
CN105828821B true CN105828821B (zh) 2019-04-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480069586.5A Active CN105828821B (zh) 2013-12-20 2014-12-18 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途

Country Status (14)

Country Link
US (1) US10376506B2 (https=)
EP (1) EP3082815B1 (https=)
JP (1) JP6448645B2 (https=)
KR (1) KR20160093025A (https=)
CN (1) CN105828821B (https=)
AU (1) AU2014368548B2 (https=)
CA (1) CA2933733A1 (https=)
CL (1) CL2016001570A1 (https=)
ES (1) ES2694352T3 (https=)
IL (1) IL246253A0 (https=)
MX (1) MX368870B (https=)
RU (1) RU2679661C1 (https=)
SG (1) SG11201604944PA (https=)
WO (1) WO2015091833A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3876938A4 (en) 2018-11-06 2022-08-10 Purdue Pharma L.P. COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2025197843A1 (ja) * 2024-03-18 2025-09-25 学校法人東京理科大学 アンヘドニアの治療又は予防用医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091075A1 (en) * 2000-12-21 2002-07-11 Carlezon Wiliam A. Treatment of depression
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
CN102014908A (zh) * 2007-11-13 2011-04-13 H.隆德贝克有限公司 具有组合的sert、5-ht3和5-ht1a活性的化合物的治疗用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
DK2001456T3 (da) * 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
PL2044043T5 (pl) 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
ES2564006T3 (es) 2009-05-25 2016-03-17 H. Lundbeck A/S Preparación de hidrocloruro de nalmefeno a partir de naltrexona
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
PH12012502153A1 (en) 2010-04-30 2013-02-04 Takeda Pharmaceuticals Co Enteric tablet
SMT201700177T1 (it) 2010-11-05 2017-05-08 H Lundbeck As Procedimento per la fabbricazione di naltrexone
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
CA2909506C (en) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
CA2909504C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091075A1 (en) * 2000-12-21 2002-07-11 Carlezon Wiliam A. Treatment of depression
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
CN102014908A (zh) * 2007-11-13 2011-04-13 H.隆德贝克有限公司 具有组合的sert、5-ht3和5-ht1a活性的化合物的治疗用途

Also Published As

Publication number Publication date
KR20160093025A (ko) 2016-08-05
WO2015091833A1 (en) 2015-06-25
EP3082815B1 (en) 2018-10-03
AU2014368548A1 (en) 2016-06-30
JP6448645B2 (ja) 2019-01-09
MX368870B (es) 2019-10-21
MX2016007947A (es) 2016-09-09
US10376506B2 (en) 2019-08-13
SG11201604944PA (en) 2016-07-28
CN105828821A (zh) 2016-08-03
JP2016540030A (ja) 2016-12-22
CA2933733A1 (en) 2015-06-25
EP3082815A1 (en) 2016-10-26
ES2694352T3 (es) 2018-12-20
IL246253A0 (en) 2016-07-31
AU2014368548B2 (en) 2019-09-19
US20160310488A1 (en) 2016-10-27
RU2016123972A (ru) 2018-01-25
RU2679661C1 (ru) 2019-02-12
CL2016001570A1 (es) 2016-12-09

Similar Documents

Publication Publication Date Title
CN105828821B (zh) 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途
Ko et al. Effects of atypical κ-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates
Benyamin et al. Opioid complications and side effects
JP2021523228A (ja) 物質乱用の治療方法
Barber Examining the use of tramadol hydrochloride as an antidepressant.
Barbera et al. The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome
Gerak et al. Methocinnamox produces long-lasting antagonism of the behavioral effects of µ-opioid receptor agonists but not prolonged precipitated withdrawal in rats
US20160256472A1 (en) Compositions and methods of administering same
Saboory et al. The long‐term effects of neonatal morphine administration on the pentylenetetrazol seizure model in rats: The role of hippocampal cholinergic receptors in adulthood
KR20200103045A (ko) 수면 장애 치료 및 예방
H Rezvani et al. Novel medication targets for the treatment of alcoholism: preclinical studies
US20070053976A1 (en) Novel combination of drugs as antidepressant
Singh et al. Opioid antagonists. I: Pharmacology and rationale for use in treating self-injury
Schifano Drug abuse: treatment and management
WO2019091870A1 (en) Stimulant abuse-deterrent compositions
EP1942891B1 (en) Novel combination of drugs as antidepressant
JP6416213B2 (ja) 気分障害患者の治療のためのナルメフェン
HK1229240A1 (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
HK1229240B (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
Schifano et al. Recreational drugs' scenario and compulsory treatment in the United Kingdom
Salloum et al. Perspectives for New Pharmacological Treatments of Alcoholism and Substance Dependence
KING et al. Medications of Abuse
Knable et al. Pharmacologic Treatments of Cocaine Dependence
JP2020517730A (ja) 心的外傷後ストレス障害を治療するための方法
Patatanian et al. Résumé-vulgarisation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant